| 1.18 0.1 (9.26%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.81 | 1-year : | 2.21 |
| Resists | First : | 1.55 | Second : | 1.89 |
| Pivot price | 1.16 |
|||
| Supports | First : | 1 | Second : | 0.83 |
| MAs | MA(5) : | 1.11 |
MA(20) : | 1.23  |
| MA(100) : | 1.6 |
MA(250) : | 2.77 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 23.3 |
D(3) : | 17.2 |
| RSI | RSI(14): 48.5 |
|||
| 52-week | High : | 7.14 | Low : | 0.99 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CARM ] has closed below upper band by 45.2%. Bollinger Bands are 46% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.18 - 1.19 | 1.19 - 1.19 |
| Low: | 1.08 - 1.08 | 1.08 - 1.09 |
| Close: | 1.17 - 1.18 | 1.18 - 1.19 |
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
Tue, 23 Jul 2024
Carisma Therapeutics, Inc. (NASDAQ:CARM) Shares Sold by Empowered Funds LLC - Defense World
Tue, 25 Jun 2024
Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors - PR Newswire
Thu, 16 May 2024
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte - PR Newswire
Sun, 12 May 2024
US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results - Simply Wall St
Thu, 09 May 2024
Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 42 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 28.6 (%) |
| Held by Institutions | 39.6 (%) |
| Shares Short | 1,950 (K) |
| Shares Short P.Month | 1,420 (K) |
| EPS | -1.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.25 |
| Profit Margin | 0 % |
| Operating Margin | -574.4 % |
| Return on Assets (ttm) | -46.4 % |
| Return on Equity (ttm) | -167.6 % |
| Qtrly Rev. Growth | 4.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.36 |
| EBITDA (p.s.) | -1.97 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -78 (M) |
| Levered Free Cash Flow | -53 (M) |
| PE Ratio | -1.06 |
| PEG Ratio | 0 |
| Price to Book value | 4.53 |
| Price to Sales | 3.25 |
| Price to Cash Flow | -0.63 |
| Dividend | 0.36 |
| Forward Dividend | 0 |
| Dividend Yield | 30.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|